No abstract

ClinicalTrials.gov NCT02232698 FUNDING: Abbott Diabetes Care, Witney, UK.

No abstract

from the study. It seems reasonable that patients with skin adverse events might decide to continue or discontinue their participation in the trial, but the management of these adverse events during this study remains unclear and not proportional to the severity of the adverse events. It would be helpful for both practitioners and patients if the authors can determine clearly what type of device-related skin adverse events require treatment or device discontinuation, or both.LP reports grants and personal fees from Sanofi and personal fees from Servier. NB and KM declare no competing interests.

No abstract